z-logo
Premium
Bone‐marrow examination in the staging of small‐cell anaplastic carcinoma of the lung with special reference to subtyping: An evaluation of 203 consecutive patients
Author(s) -
Hirsch Fred,
Hansen Heine H.,
Dombernowsky Per,
Hainau Bo
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197706)39:6<2563::aid-cncr2820390638>3.0.co;2-i
Subject(s) - medicine , subtyping , anaplastic carcinoma , pathology , bone marrow , lung , carcinoma , oncology , radiology , computer science , programming language
Histologic examination of bone‐marrow from the posterior iliac crest was routinely done as a pretreatment staging procedure in 203 consecutive patients with small‐cell anaplastic carcinoma of the lung. Subtyping of the patients according to the WHO classification included 27.8% with “fusiform” cell type (WHO II,1), 28.3% with “polygonal” cell type (WHO II,2), 42.8% with “lymphocyte‐like” cell type (WHO II,3), and 1.1% with mixed types (WHO II,4). Bone‐marrow involvement was found in 17.2%. No significant difference was observed among the histological subtypes with regard to bone‐marrow involvement. A comparison of bone‐marrow biopsy and aspiration in patients investigated with both procedures showed that aspiration alone was diagnostic in nine of 24 (38%) positive patients as compared with two of 24 (8%) with biopsy alone, while in the remaining 13 patients (54%) both procedures were positive. Of the 35 patients with positive bone‐marrow examination, 77% had no other evidence of distant metastatic disease if liver metastases identified by peritoneoscopy and liver biopsy are excluded as a staging procedure. With the exception of thrombocytopenia which was observed in six patients, with bone‐marrow metastases, hematological findings were of little value in detecting bone‐marrow involvement.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here